Meyer Andrew Hollman 4
4 · Janux Therapeutics, Inc. · Filed Oct 30, 2025
Insider Transaction Report
Form 4
Meyer Andrew Hollman
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-10-28$10.59/sh+6,666$70,593→ 98,804 total - Sale
Common Stock
2025-10-28$30.06/sh−16,665$500,987→ 82,139 total - Exercise/Conversion
Stock Option (right to buy)
2025-10-28−9,999→ 77,333 totalExercise: $4.21Exp: 2031-03-09→ Common Stock (9,999 underlying) - Exercise/Conversion
Common Stock
2025-10-28$4.21/sh+9,999$42,096→ 92,138 total - Exercise/Conversion
Stock Option (right to buy)
2025-10-28−6,666→ 121,434 totalExercise: $10.59Exp: 2031-05-13→ Common Stock (6,666 underlying)
Footnotes (3)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
- [F2]The weighted average sale price for the transaction reported was $30.0622 and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.